Skip to Main Content

Paper Details

Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
Arthritis Rheumatol
43
2020
16S ribosomal RNA, C albicans, CD, Candida albicans, Crohn's disease, IL, IL-17, IL-17A, IL-17E, IL-17i, IL-23, IL-25, IL-25/IL-17E-producing cells, IL-25/IL-17E-producing tuft cells, ILC2s, Interleukin-17, Interleukin-25, Intestinal Inflammation, PsA, SpA, Spondyloarthritis, TNFi, Th17, fatty acid, fatty acids, gut inflammation, interleukin-17A, internal transcribed spacer, intestinal dysbiosis, intestinal inflammation, patients, psoriatic arthritis, spondyloarthritis, tumor, tumor necrosis factor, type 2 innate lymphoid cells
Author NameAffiliation
Drew R JonesNew York University School of Medicine
Pieter C DorresteinSkaggs School of Pharmacy and Pharmaceutical Sciences at the University of California
Richard BonneauSimons Foundation, New York University, and Courant Institute of Mathematical Sciences
  • 1 - 3

Datasets

Release 1.2